Is Wegovy Ozempic? The Same Drug, Two Very Different Licences

So are wegovy and ozempic actually the same thing?

At a chemical level, yes. Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and influences the brain's hunger signals. Novo Nordisk developed and manufactures both. The molecule is identical.

Where they diverge is in regulatory authorisation. In the UK, the MHRA licenses medicines for specific indications, and semaglutide has been authorised under two separate brand names for two separate purposes. Ozempic's authorisation covers blood-glucose control in type 2 diabetes. Wegovy's authorisation covers weight management. A broader look at semaglutide's UK history shows how the same compound has accumulated distinct approvals over several years.

The doses differ too. Ozempic is available at 0.5mg and 1mg (and 2mg for diabetes). Wegovy's titration schedule runs from 0.25mg up to a 2.4mg maintenance dose, with the MHRA also having approved a 7.2mg single-dose pen in April 2026 for adults with a BMI of 30 or above. Higher doses were developed specifically for the weight-management trials rather than for diabetes control, which is part of why separate products exist at all.

Why does it matter which brand a prescriber uses?

Practically speaking, this distinction shapes what a prescriber can legally and ethically write on a prescription. In the UK, prescribing Ozempic to someone who doesn't have type 2 diabetes, purely for weight loss, would be off-label, meaning it falls outside the product's MHRA-approved indication. Off-label prescribing isn't automatically unsafe, but it carries a different accountability standard and isn't supported by the same body of evidence the regulator assessed.

There is also a supply dimension. During the semaglutide shortage that ran through much of 2023 and into 2024, some prescribers considered Ozempic as an alternative source of semaglutide for weight-loss patients. The MHRA and NHS were clear that this was not an appropriate substitute and that Ozempic supplies should be protected for people with diabetes who depend on it. You can read more about how the two products relate to each other on the Wegovy versus Ozempic page, which goes into the supply and dose distinctions in greater detail.

For anyone considering weight management treatment, the relevant licensed product in the UK is Wegovy. The Wegovy treatment overview covers the full titration schedule and what clinical trials have shown about average weight loss at the licensed doses.

What IS licensed for weight loss in the UK, and who qualifies?

For people looking at ozempic wegovy uk options, here is a plain summary of what is actually available through a legitimate UK prescription for weight management.

Wegovy (semaglutide injection) is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, high blood pressure, type 2 diabetes, dyslipidaemia, and obstructive sleep apnoea are among those that count. NICE has also recommended Wegovy within specialist weight management services, subject to conditions including a maximum treatment duration of two years under NHS commissioning. The NHS medicines page for semaglutide covers what to expect, common side effects, and who should not use it.

Mounjaro (tirzepatide) is the other licensed option, a dual GIP and GLP-1 receptor agonist with its own NICE recommendation (TA1026, December 2024). In clinical trials it produced greater average weight reduction than semaglutide at comparable doses, though which medicine suits a specific person depends on their health history, not trial averages. The weight-loss treatments overview sets out both options side by side.

Ozempic sits outside this list. It is not licensed for weight management, and at nume it is not dispensed for that purpose. If you've been on Ozempic for diabetes and want to understand how switching works, there is guidance on moving from Ozempic to Wegovy that covers the clinical considerations involved, that conversation belongs with your prescriber and your diabetes team.

What about Rybelsus, is that Ozempic or Wegovy?

This comes up often. Rybelsus is oral semaglutide (3mg, 7mg and 14mg tablets), licensed in the UK for type 2 diabetes, the same indication as Ozempic, not weight management. It is not the same as the Wegovy tablet, which received MHRA approval in June 2026 as the UK's first oral GLP-1 medicine for weight loss, using a 1.5mg to 25mg dose schedule that is entirely separate from Rybelsus.

The way to think about it: Novo Nordisk has built a family of semaglutide products, and the brand name tells you the intended use. Wegovy (injection or tablet) means weight management. Ozempic and Rybelsus mean type 2 diabetes. Mixing those up carries real consequences, not least because the dose ranges and monitoring expectations differ. A thorough explanation of how Ozempic and Wegovy work explains the shared GLP-1 mechanism and where the clinical paths diverge.

If you're thinking about Wegovy for weight management and want to know whether it's clinically appropriate for your situation, our prescribers are happy to assess. There's no charge for the consultation, and you can check treatment options without commitment at the consultation page. Understanding the cost side first? The Wegovy cost page covers private pricing context honestly.